ClinicalTrials.gg
Active, not recruitingNCT06922045Updated Aug 12, 2026

Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients

A Phase 3 interventional study of STSP-0601 for Injection in Hemophilia, sponsored by Jiangsu BioJeTay Biotechnology Co., Ltd.. Active, not recruiting at 18 sites in China. Open to participants aged 12 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Jiangsu BioJeTay Biotechnology Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
12 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 93 studies in Hemophilia A with a site in China — 28 open to participants now, 39 under way, 19 of them phase 3. Hemophilia A · China.

Enrollment
49th of 80
40 · median 54
Started
2025
with 4 others
Phase 3
41 of 93
9 open now
Primary completion
2026-09
later than 9 of 38 live
Registered
79th of 93
by date

Among the 93 studies in Hemophilia A with a site in China, this one is the 49th largest by enrollment of the 80 interventional ones that give a count, is one of 5 that started in 2025, is one of 41 in phase 3, reaches primary completion later than 9 of the 38 other live ones, and was the 79th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

28 of the 93 studies in Hemophilia A with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Hemophilia A with a site in China, or all of them as a file.
02

Study summary

This study will assess the efficacy of multiple-dose of STSP-0601 for the treatment of bleeding episodes in hemophilia A or B patients with inhibitor

03

Conditions studied

  • Hemophilia

Browse trials for

04

Who can participate

Ages eligible
12 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 12 ≤age≤70 years of age.
  2. Hemophilia A or B patients.
  3. Peak historical inhibitor titer ≥ 5 BU and a positive inhibitor test when enrolled.
  4. Establish proper venous access.
  5. There were at least 3 bleeding events that required treatment occurred in the past 6 months before screening.
  6. Agree to use adequate to avoid pregnancy.
  7. Provide signed .

Exclusion criteria

Exclusion Criteria:

  1. Have any coagulation disorder other than hemophilia.
  2. Plan to receive prophylactic treatment of coagulation factor during the trail.
  3. Patients plan to receive Emicizumab during the trial.
  4. Patients received anticoagulant or antifibrinolytic therapy 7 days before the first administration or plan to receive these drugs during the trial.
  5. Have a history of arterial and/or venous thrombotic events.
  6. \<100×109/L.
  7. \<90g/L.
  8. Severe liver or kidney disease.
  9. Severe bleeding event occurred within 4 weeks before the first administration.
  10. Accepted major operation or blood transfusion within 4 weeks before the first administration.
  11. Have a known allergy to STSP-0601.
  12. Pregnant, lactating, or blood pregnancy test positive female subjects
  13. Participate in other clinical research within 4 weeks before enrollment (except for participating in prothrombin complex, FVII, FVIIa, FVIII, FIX trails).
  14. Within 1 day before the first administration, FVII, FVIIa, tranexamic acid, and aminocaproic acid were used. Within 3 days before the first administration, prothrombin complex, FVIII, and FIX were used. Within 4 weeks, treatment with Emicizumab was received.
  15. Patients not suitable for the trail according to the judgment of the investigators.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Continuous administration of STSP-0601

    Drug: STSP-0601 for Injection

Interventions

  • Evaluation of the Efficacy of Single-Dose and Continuous Administration of STSP-0601 Injection for the Treatment of Bleeding in Patients with Hemophilia A or B with Inhibitors

06

What researchers measure

Primary outcomes

  1. 12 hours effective hemostasis rate

    Time frame: 12 hours after the first administration

Secondary outcomes

  1. Effective hemostasis rate at the first 12 hours bleeding visit

    Time frame: 12 hours after the first administration

  2. 12 hours excellent + good rate

    Time frame: 12 hours after the first administration

  3. The number of medication required for effective hemostasis within 12 hours

    Time frame: 12 hours after the first administration

  4. The amount of medication (U/kg) required for effective hemostasis within 12 hours

    Time frame: 12 hours after the first administration

  5. 8-hours effective hemostasis rate

    Time frame: 8 hours after the first administration

  6. 8-hours excellent + good rate

    Time frame: 8 hours after the first administration

  7. Complete + significant relief rate

    Time frame: 4 hours, 8 hours, 12 hours, 24 hours after the first administration

  8. The time to achieve complete/significant remission after the first administration

    Time frame: From the time after the first administration until within 72 hours after the last administration

  9. Rescue treatment rate

    Time frame: Within 72 hours after the last administration

  10. The time from the onset of bleeding to complete/significant relief

    Time frame: Within 72 hours after the last administration

  11. The effective hemostasis rate of the target joint

    Time frame: From 12 hours after the first administration to 72 hours after the last administration

07

Study locations

18 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Sep 2026, 18 months after the start.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 18 months is below that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2025
First posted
Apr 10, 2025
StartActual
Mar 26, 2025
Primary completionEst.
Sep 2026
CompletionEst.
Mar 2027
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06922045
Lead sponsor
Jiangsu BioJeTay Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Apr 10, 2025
Start date
Mar 26, 2025
Primary completion
Sep 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Aug 12, 2026

Study contacts

Lei Zhang, Ph.D
principal investigator · Hospital of Hematology, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: STSP-0601

Start the discussion